866-997-4948(US-Canada Toll Free)

Candidiasis Therapeutics Market - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Therapeutic Area

No. of Pages : 39 Pages


GlobalData, the industry analysis specialist, has released a new report, “Candidiasis Therapeutics Market - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global candidiasis therapeutics market. The report identifies the key trends shaping and driving the global candidiasis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global candidiasis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. 

GlobalData forecasts the global candidiasis therapeutics market to grow at 5.9% annually for the next seven years to reach $2,504m by 2017. It was valued at $1,572m in 2009. This moderate growth will primarily be supported by an increase in the disease incidence rate and the launch of two promising pipeline molecules during the forecast period. The growth of the candidiasis therapeutics market during the forecast period will not be much higher than the rate at which it grew between 2001 and 2009. This is primarily attributed to two reasons. Firstly, the candidiasis therapeutics market is dominated by generic products which generate less revenue per unit volume sold. Second, the pipeline of the candidiasis therapeutics market is weak, with a small number of molecules across different stages of development. However, the continued uptake of the currently marketed products and the launch of some of the late-stage pipeline molecules will sustain market growth during the forecast period. 

Scope

The report provides information on the key drivers and challenges in the candidiasis therapeutics market. Its scope includes:

  • Annualized global candidiasis therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • The candidiasis pipeline is weak, with only seven molecules in various phases of clinical development. Phase III includes two me-too drug and one combination. On an overall basis, one first-in-class product, PEV7, is in Phase I development.
  • Analysis of the current and future market competition in the global candidiasis therapeutics market. The key market players operating in this market are Pfizer, Janssen Pharmaceutica Products, Johnson & Johnson, Astellas/Roche and Merck
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the candidiasis therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global candidiasis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global candidiasis therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global candidiasis therapeutics market landscape? - Identify, understand and capitalize.
Table of Content

1 Table of contents 3

1.1 List of Tables 5
1.2 List of Figures 5

2 Candidiasis : Introduction 6

2.1 Disease Overview 6
2.2 GlobalData Pipeline Report Guidance 6

3 Candidiasis : Market Characterization 7
3.1 Overview 7
3.2 Candidiasis Therapeutics Market Size 7
3.3 Candidiasis Therapeutics Market Forecast and Compound Annual Growth Rate 7
3.4 Drivers and Barriers for the Candidiasis Therapeutics Market 9
3.4.1 Drivers for the Candidiasis Therapeutics Market 9
3.4.2 Barriers for the Candidiasis Therapeutics Market 9
3.5 Opportunity and Unmet Need 9
3.6 Key Takeaway 10

4 Global Candidiasis Therapeutics Market: Competitive Assessment 11
4.1 Overview 11
4.2 Strategic Competitor Assessment 11
4.3 Product Profiles of the Major Marketed Products in Candidiasis Therapeutics Market - Azole Group 12
4.3.1 Fluconazole 12
4.3.2 Itraconazole (Oral Solution) 14
4.3.3 Miconazole 15
4.3.4 Clotrimazole 17
4.3.5 Ketoconazole 17
4.4 Product Profiles of the Major Marketed Products in the Candidiasis Therapeutics Market Echinocandins Class 18
4.4.1 Anidulafungin (ERAXIS) 18
4.4.2 Micafungin 20
4.5 Product Profiles of the Major Marketed Products in Candidiasis Therapeutics Market Polyene class 23
4.5.1 Nystatin (Oral Suspension) 23
4.6 Key Takeaway 24

5 Global Candidiasis Therapeutics Market : Pipeline Assessment 25
5.1 Overview 25
5.2 Strategic Pipeline Assessment 25
5.2.1 Technology Trends Analytic Framework 25
5.3 Candidiasis Therapeutics Market Promising Drugs under Clinical Development 27
5.4 Molecule Profile for Promising Drugs under Clinical Development 27
5.4.1 Isavuconazole 27
5.5 Candidiasis Therapeutics Market Clinical Pipeline by Mechanism of Action 28
5.6 Candidiasis Pipeline Pipeline by Clinical Phases of Development 29
5.6.1 Candidiasis Regulatory Filing and Phase III Clinical Pipeline 29
5.6.2 Candidiasis Phase II Clinical Pipeline 29
5.6.3 Candidiasis Therapeutics Market Phase I Clinical Pipeline 29
5.7 Key Takeaway 30

6 Global Candidiasis Therapeutics Market : Implications for Future Market Competition 31

7 Global Candidiasis Therapeutics Market : Future Players in Candidiasis Market 32

7.1 Introduction 32
7.2 Demegen, Inc. 32
7.2.1 Overview 32
7.2.2 Business Description 32
7.2.3 Candidiasis Product Portfolio 33
7.3 Basilea Pharmaceutica Ltd. 33
7.3.1 Overview 33
7.3.2 Business Description 33
7.3.3 Infectious Disease Pipeline Product Portfolio 33
7.3.4 Candidiasis Product Portfolio 33

8 Candidiasis Therapeutics Market : Appendix 34
8.1 Market Definitions 34
8.2 Abbreviations 34
8.3 Research Methodology 34
8.3.1 Coverage 35
8.3.2 Secondary Research 35
8.3.3 Forecasting 35
8.3.4 Primary Research 37
8.3.5 Expert Panel Validation 38
8.4 Contact Us 38
8.5 Disclaimer 38
8.6 Sources 38

List of Table


Table 1: Candidiasis Therapeutics Market, Global, Revenue ($m), 2001-2009 8
Table 2: Candidiasis Therapeutics Market, Global, Forecast ($m), 2009-2017 8
Table 3: Fluconazole Clinical Study Details (For Vaginal Candidiasis) 13
Table 4: Fluconazole Clinical Study Details (For Immunocompromised Children With Oropharyngeal Candidiasis) 14
Table 5: Miconazole (Vusion -Ointment for Topical Use) Clinical Trial Details 16
Table 6: ERAXIS Clinical Trial Details- Efficacy Analysis: Global Success in patients with Candidemia and other Candida infections (MITT Population) 19
Table 7: ERAXIS Clinical Trial Details - Endoscopy Results in Patients with Esophageal Candidiasis (Clinically Evaluable Population) - Endoscopic Response at End of Therapy 20
Table 8: ERAXIS Clinical Trial Details - Endoscopy Results in Patients with Esophageal Candidiasis (Clinically Evaluable Population) - Endoscopic Relapse Rates at Follow-up, Two Weeks Post-Treatment 20
Table 9: Micafungin (Mycamine) Clinical Trial Details - Efficacy Analysis: Treatment Success in Patients in Study 03-0-192 with Candidemia and Other Candida Infections 21
Table 10: Micafungin (Mycamine) Clinical Trial Details - Endoscopic, Clinical and Mycological Outcomes for Esophageal Candidiasis at End of Treatment 22
Table 11: Micafungin (Mycamine) Clinical Trial Details - Relapse of Esophageal Candidiasis at Week 2 and through Week 4 Post-Treatment in Patients with Overall Therapeutic Cure at the End of Treatment 22
Table 12: Major Marketed Products Comparison in the Candidiasis Therapeutics Market 24
Table 13: Candidiasis Therapeutics Market Most Promising Drugs Under Clinical Development 27
Table 14: Candidiasis Therapeutics Market, Regulatory Filing and Phase III Clinical Pipeline 29
Table 15: Candidiasis Therapeutics Market, Phase II Clinical Pipeline 29
Table 16: Candidiasis Therapeutics Market, Phase I Clinical Pipeline 29
Table 17: Demegen, Inc. Infectious Disease Pipeline 32
Table 18: Basilea Pharmaceutica Ltd. Infectious Disease Pipeline 33

List of Chart


Figure 1: Candidiasis Therapeutics Market, Global, Revenues ($m), 20012009 7
Figure 2: Candidiasis Therapeutics Market, Global, Forecast Revenues ($m), 20092017 8
Figure 3: Opportunity and Unmet Need in the Candidiasis Therapeutics Market 10
Figure 4: Strategic Competitor Assessment of the Marketed Products for Candidiasis 12
Figure 5: Technology Trends Analytic Framework of the Candidiasis Pipeline 26
Figure 6: Technology Trends Analytic Framework of the Candidiasis Pipeline Description 26
Figure 7: Candidiasis Therapeutics Market, Clinical Pipeline by Mechanism of Action (%) 28
Figure 8: Candidiasis Therapeutics Market, Pipeline by Phase of Clinical Development (%) 29
Figure 9: Implications for Future Market Competition in the Candidiasis Therapeutics Market 31
Figure 10: Candidiasis Therapeutics Market, Clinical Pipeline by Company 32
Figure 11: GlobalData Market Forecasting Model 37

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *